Tobira Therapeutics Inc. (NASDAQ:TBRA)’s share price was up 5.1% during mid-day trading on Thursday . The company traded as high as $4.38 and last traded at $4.35, with a volume of 264,056 shares changing hands. The stock had previously closed at $4.14.

A number of equities analysts have issued reports on TBRA shares. HC Wainwright started coverage on Tobira Therapeutics in a research note on Monday, April 11th. They set a “buy” rating and a $22.00 price target for the company. Zacks Investment Research lowered Tobira Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. Leerink Swann reaffirmed a “buy” rating on shares of Tobira Therapeutics in a research note on Monday, May 2nd. Cowen and Company reaffirmed a “buy” rating on shares of Tobira Therapeutics in a research note on Tuesday, May 10th. Finally, Cantor Fitzgerald started coverage on Tobira Therapeutics in a research note on Wednesday, July 6th. They set a “buy” rating and a $27.00 price target for the company. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $16.95.

The company’s market capitalization is $81.09 million. The company’s 50 day moving average price is $10.86 and its 200 day moving average price is $8.63.

Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.12. Analysts forecast that Tobira Therapeutics Inc. will post ($2.49) earnings per share for the current fiscal year.

In other news, major shareholder A/S Novo sold 66,814 shares of Tobira Therapeutics stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $13.04, for a total value of $871,254.56. Following the completion of the transaction, the insider now owns 2,073,022 shares in the company, valued at $27,032,206.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP bought a new position in shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.